In its recently published report titled “Crohn’s Disease Market: Global Industry Analysis and Forecast, 2016-2024,” Persistence Market Research presents an outlook of the global Crohn’s disease market for the projected period of eight years. The primary objective of the report is to offer insights into developments in the global Crohn’s disease market that are affecting global businesses and enterprises. The report provides updates on market opportunities and insights to understand the growth and performance of the key segments of the global Crohn’s disease market. Through extensive research, Persistence Market Research analysts have studied how the different market dynamics are likely to impact the current and future scenario of the global Crohn’s disease market, thereby providing useful insights to market players to plan their future business strategies. The report covers the global Crohn’s disease market performance in terms of revenue contribution from various segments. This report also includes Persistence Market Research’s exclusive analysis of key trends, drivers, restraints and opportunities, which are influencing the growth of the global Crohn’s disease market. Impact analysis of key growth drivers and restraints are included in this report to better equip clients with crystal clear decision-making insights.
The report on the global Crohn’s disease market begins with an overview of Crohn’s disease, types of drugs used for treatment and key market definitions. The analysts also present an executive summary along with market taxonomy where the global Crohn’s disease market is segmented on the basis of drug type, distribution channel and region. The analysts also offer an unbiased analysis of overall market approach, target geographies and different strategies adopted by the key players across the globe to strengthen their market position in the next few years. Another section of the report consists of Crohn’s disease epidemiology, treatment paradigms and medications for the disease. The value chain of the market included in this report adds focus towards enhancing patient safety and product innovation that are key features expected to emerge in the global Crohn’s disease market.
The report concludes with a study of the market performance of some of the top companies operating in the global Crohn’s disease market. Persistence Market Research analysts have profiled some of the leading market players and presented a detailed analysis of their overall business performance and a comprehensive evaluation of their short-term and long-term business and go-to-market strategies. This section is intended to provide report audiences with a dashboard view of the competitive landscape of the global Crohn’s disease market.
By Drug Type
By Distribution Channel
Exclusive research methodology
Yearly change in inflation rate has not been factored in while forecasting market numbers. While researching this report indicators such as R&D expenditure, research funding from government and non-profit organizations etc. have been considered to arrive at the indicated market numbers. A bottom-up approach has been used to evaluate market numbers for each product category, while top-down approach has been used to counter-validate the reached numbers. The analysts have done in-depth secondary research to ascertain overall market size, top industry players, and top products. In order to conduct expert and industry interviews, Persistence Market Research has formulated a detailed discussion guide, post which the analysts have conducted interviews with industry experts, industry players, retailers and distributors.
Market examination on Year-on-Year growth parameter
It is imperative to note that in an ever-fluctuating global economy, the report not only conducts forecasts in terms of CAGR but also analyzes the market on the basis of key parameters such as Year-on-Year (Y-o-Y) growth to understand the predictability of the market and to identify the right opportunities in the global Crohn’s disease market. Another key feature of this report is the analysis of the global Crohn’s disease market by region, drug type, by distribution channel and its revenue forecast in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global Crohn’s disease market. In order to understand key market segments in terms of growth and performance in the global Crohn’s disease market, Persistence Market Research has developed a market attractiveness index to help providers identify real market opportunities.
Anti-inflammatory drugs segment expected to reach a CAGR of 4.2% during the projected period
The anti-inflammatory drugs segment is expected to exhibit the highest growth over the forecast period. Anti-inflammatory drugs is the fastest growing segment of the global Crohn’s disease market, which is expected to grow from over US$ 780 Mn to more than US$ 1,000 Mn during the forecast period. Anti-inflammatory drugs segment is expected to create absolute $ opportunity of more than US$ 20 Mn in 2017 over 2016. This segment is leading the global Crohn’s disease market by expanding at a CAGR of 4.2% over the assessment period. It is also expected to be the most lucrative segment in global Crohn’s disease market.
No permanent cure for the disease boosts the anti-inflammatory drugs segment in the global Crohn’s disease market
Increasing incidence of inflammatory bowel syndrome i.e. Crohn’s disease and ulcerative colitis is the prime factor responsible for the progress of the anti-inflammatory drugs segment. The segment is likely to show sustained growth as Crohn’s disease is associated with several other conditions such as inflammation, bacterial infection, diarrhoea and mild pain. To manage such conditions, healthcare practitioners largely prescribe anti-inflammatory drugs such as Prednisone, Budesonide and Budesonide-MMX. This particular factor is fueling the development of the anti-inflammatory drugs segment in the global Crohn’s disease market. Another factor which is creating positive impact on this segment is the fact that there is no permanent cure for the disease. Technically, Crohn’s disease has no permanent cure and therefore patients suffering from this particular disease and its associated conditions have to depend on anti-inflammatory and other drugs to obtain relief. Crohn’s disease drug manufacturers are focusing on the commercial distribution of medicines through retail pharmacies and online portals. These channels widely distribute anti-inflammatory drugs and corticosteroids with and/or without prescription. Consumers can also avail discounts on bulk purchase of medicines through online portals. Easy product availability and price discounts contribute significantly to the robust growth of the anti-inflammatory drugs segment of the global Crohn’s disease market.
Lack of education and ignorance is likely to hamper the development of the anti-inflammatory drugs segment
In countries such as Africa and Nigeria the diagnosis rate of inflammatory bowel syndrome is substantially low. Moreover, around 30% of the diagnosed population does not take total treatment for an average duration of six months. Thus, lack of education and a casual attitude towards treatment duration is a factor that is expected to hamper revenue growth of the anti-inflammatory drugs segment of the global Crohn’s disease market. On the other hand, patients suffering from Crohn’s disease in India and China are adopting alternative treatment options such as Ayurveda and Homeopathy, which is another significant factor expected to hinder the progress of the anti-inflammatory drugs segment during the forecasted period.
Anti-inflammatory drugs segment is expected to be the most lucrative market segment in North America
Anti-inflammatory drugs segment is anticipated to be the most lucrative segment in the North America Crohn's disease market with a market attractiveness index of 2.1, followed by the Latin America Crohn's disease market where the segment records a market attractiveness index of 1.7. The reason for the growth of the segment in North America is that the U.S is the largest Crohn’s disease market in the region. In North America, the anti-inflammatory drugs segment is expected to register a CAGR of 4.3% followed by Europe, where the segment is anticipated to exhibit 4.0% Compound Annual Growth Rate.
Perriago Company plc enters into an agreement with AstraZeneca – a company dealing in anti-inflammatory drugs
In November 2015, U.S. based Perriago Company plc entered into an agreement with U.K based AstraZeneca for the divestment of US rights to Entocort®, used for the treatment of Crohn’s disease. AstraZeneca particularly deals with Budesonide, which is an anti-inflammatory drug. In the Asia Pacific region, the potential market for anti-inflammatory drugs is currently in the growth phase and leading companies are raising funds for the development of cost-effective anti-inflammatory drugs.